ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib

BACKGROUND: ROS1 rearrangements are validated drivers in lung cancer, which have been identified in a small subset (1–2%) of patients with non-small cell lung cancer (NSCLC). To date, 18 fusion genes of ROS1 have been identified in NSCLC. The ALK inhibitor (crizotinib) exhibits therapeutic effect ag...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:BMC Cancer
Päätekijät: Xu, Shuguang, Wang, Wenxian, Xu, Chunwei, Li, Xingliang, Ye, Junhui, Zhu, Youcai, Ge, Ting
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2019
Aiheet:
Case Report
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6683537/
https://ncbi.nlm.nih.gov/pubmed/31382924
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-5948-y
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia